Source link : https://www.newshealth.biz/health-news/tafasitamab-based-combination-boosts-pfs-in-relapsed-refractory-follicular-lymphoma/
SAN DIEGO — Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and rituximab (Rituxan) resulted in a significant and clinically meaningful improvement in progression-free survival (PFS) for patients with relapsed/refractory follicular lymphoma, the randomized phase III inMIND trial showed. Patients who received the combination had a median PFS of […]
Author : News Health
Publish date : 2024-12-11 13:54:53
Copyright for syndicated content belongs to the linked Source.